Patient Outcomes Using HIP7 Software as Compared to Conventional THA

A Prospective, Multi-center, Randomized Controlled Study to Evaluate Patient Outcomes Using Hip7 Software as Compared to Conventional Surgical Technique in S+N Total Hip Arthroplasties (THA)

The study is designed to demonstrate how Hip7 software can lead to improved patient outcomes compared to conventional procedures with standard instrumentation for total hip arthroplasties (THA) surgery.

Study Overview

• Status: Withdrawn
• Conditions: Hip Replacement
• Intervention / Treatment: Device: Hip7 Software on Kick/ CORI platforms; Device: Conventional surgical procedures

Detailed Description

This study is a prospective, multi-center, randomized, controlled clinical study in total hip arthroplasties (THA) surgery. The subjects meeting the inclusion/exclusion criteria specified in the protocol will receive THA using either Hip7 software or conventional instrumentation.

The clinical follow-up evaluation will be performed preoperatively (Baseline), operatively, 6 weeks, 6 and 12 months after surgery using patient reported outcome measures regarding their general health, hip and physical abilities, quality of life and pain level.

• Study Type: Interventional
• Phase: Not Applicable

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. The subject or legal guardian must provide written informed consent (reference section 7.5).
2. Subjects eighteen (18) years or older and considered skeletally mature.
3. Willing and able to make all required study visits.
4. Able to follow instructions and deemed capable of completing the FJS, OHS, HOOS and EQ-5D-5L questionnaires.
5. Subject requires a THA as a primary indication.
6. Subject is a suitable candidate for implanting specific S+N implant system in the investigator's judgement.
7. Subject agrees to consent to and to follow the study visit schedule (as defined in the study protocol and informed consent form), by signing the Ethics Committee (EC) approved informed consent form.
8. Subject plans to be available through 12 months postoperative follow-up
9. Routine radiographic assessment including CT and X-ray is possible.

Exclusion Criteria:

1. Contraindicated for robotic THA or POLAR3 hip implant.
2. Participation in the treatment period of another clinical trial within thirty (30) days of Visit 1, or during the study.
3. Women who are pregnant, nursing, or of child-bearing potential who are not utilizing highly effective birth control measures.
4. Any subject that meets the definition of a Vulnerable Subject per International Organization for Standardization (ISO) 14155:2011 Section 3.44.
5. Subjects who have participated previously in this trial through THA on their other hip.
6. Subjects with a history of poor compliance with medical treatment (i.e have mental illness, drug or alcohol addiction).
7. Subjects who need a THA procedure on the index joint as a revision for a previously failed surgery.
8. Subjects suspected to need bilateral surgery in the next 12 months.
9. Subject has received THA on the opposing hip within the previous 6 months.
10. Subjects not understanding the language used in the Informed Consent Form.
11. Subjects with an active infection or sepsis (treated or untreated).
12. Subjects morbidly obese with a BMI greater than 40.
13. Subjects in the opinion of the Investigator, has advanced osteoarthritis or joint disease at the time of surgery and are better suited for an alternate procedure.
14. Subjects that have condition(s) that may interfere with the THA survival or outcome (i.e., Paget's or Charcot's disease, vascular insufficiency, muscular atrophy, uncontrolled diabetes, moderate to severe renal insufficiency or neuromuscular disease, or an active, local infection).
15. Subjects, in the opinion of the Investigator, has a neuromuscular disorder that prohibited control of the index joint.
16. Subjects with a medical or physical condition that, in the opinion of the Investigator, would preclude safe subject participation in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Hip7 Software on Kick/ CORI platforms; Subjects will receive total hip arthroplasty surgery using Hip7 on Kick or CORI platform utilizing R3 Polarstem implants.	Device: Hip7 Software on Kick/ CORI platforms; Total hip arthroplasty surgery using Hip7 software on Kick or CORI platforms using R3 Polarstem implants.
ACTIVE_COMPARATOR: Conventional procedures with standard, manual instrumentation and digital templating techniques; Subjects will receive total hip arthroplasty surgery using conventional procedures with standard instrumentation and digital templating techniques utilizing R3 Polarstem implants.	Device: Conventional surgical procedures; THA surgery using standard, manual instrumentation and digital templating techniques using R3 polarstem implants.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Forgotten Joint Score (FJS)	Compare Forgotten Joint Score (FJS) utilizing Hip7 software on Kick & CORI platforms with POLAR3 system to conventional procedures with standard instrumentation and digital templating techniques at 12 months post-operation. The FJS-12 Questionnaire comprises measures for assessment of joint-specific patient reported outcomes that focuses on subject's awareness of replaced joint in everyday life. Joint awareness defined as any unintended perception of a joint. Subjects rate awareness of their hip arthroplasty in 12 questions with a 5-point Likert response format: "Never", "almost never", "seldom", "sometimes" and "mostly". Scores are summed & linearly transformed in a 0-100 scale with a high value reflecting subject's ability to forget the replaced hip joint during daily living activities.	12 months post-surgery

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Frequency of Reduction of Outliers	Frequency of reduction of outliers* with Hip7 software as compared to conventional procedures (as defined by literature) using digital templating techniques for posterior and direct anterior approaches *Outliers are defined as acetabular component placement outside the desired "safe zone". Two most commonly used safe zones are described by Lewinnek and Callanan with the inclination and anteversion values outlined below: Callanan Safe Zone -- Anteversion between 5-25 degrees, Inclination between 30-45 degrees. Lewinnek - Anteversion between 5-25 degrees, Inclination between 30-50 degrees [i.e. 40° ± 10° and 15° ± 10°].	6 weeks post surgery
Patient Reported Outcomes: Hip Disability and Osteoarthritis Outcome Score (HOOS)	The HOOS is developed as an instrument to assess the subject's opinion about their hip and associated problems. HOOS consists of 5 subscales: Pain, other Symptoms, Function in daily living (ADL), Function in sport and recreation (Sport/Rec) and hip related QOL. The last week is taken into consideration when answering the questions. Standardized answer options are given (5 Likert boxes) and each question gets a score from 0 to 4. A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is calculated for each subscale.	12 months post-surgery
Patient Reported Outcomes: Oxford Hip Score (OHS)	The OHS is a 12-item questionnaire for patients who undergo total hip replacement (THR) to complete. Patients are asked to reflect on their pain and functional ability over the previous four weeks. There are two domains (pain and function) with six items or questions in each. Each item has four possible responses. Responses were from 1 = least difficult to 4= most difficult. Item scores are summed to give a total score from anywhere between 0 and 48. The lower the score, the better the outcome.	12 months post-surgery
Patient Reported Outcomes: EuroQol (European Quality of Life) five-dimensional Five-level (EQ-5D-5L)	The EQ-5D-5L questionnaire consists of two parts. Part one is the descriptive system to describe the subject's health state and consists of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The subject indicates their health state by marking the most appropriate statement in each of the 5 areas. Responses are converted to scores ranging from less than 0 to 1.0 with high scores representing higher health utility. Part two is the EQ Visual Analog Scale (VAS) that records the subject's self-rated health on a vertical visual analogue scale. Scale ranges from 0-100 with 100 labelled "The best health you can imagine" and 0 "The worst health you can imagine".	12 months post-surgery
Cup placement accuracy	To demonstrate cup placement accuracy (defined as the difference between inclination, anteversion, leg length, and offset target) from the Computerized Tomography [CT]).	6 weeks post-op
Assess Pelvic Tilt at 6 Weeks	A CT scan will assess pelvic tilt (angle of pelvic bone in relation to spine and femur)	6 weeks post-op
Assess Range of Motion of Femur at 6 Weeks	Medical staff will measure angles of femur movement in order to assess active range of motion. Active range of motion measures include angles of active flexion, abduction, adduction, external rotation and internal rotation.	6 weeks post-op
Assess Frequency of Femur Head Dislocation at 6 Weeks	Whether the subject experienced femoral head dislocation will be assessed at 6 weeks post op. Femoral head dislocation will be determined based on the count of participants with joint dislocation responses recorded by the investigator in the Adverse Events Case Report Form (CRF).	6 weeks post-op

Collaborators and Investigators

• Sponsor: Smith & Nephew Orthopaedics AG
• Investigators: Principal Investigator: Edward T Davis, MB ChB, M.Sc, PGCME, FRCS(T&O), The Royal Orthopaedic Hospital NHS Foundation Trust; Principal Investigator: Yixin Zhou, Beijing Jishuitan Hospital

Study record dates

Study Major Dates

• Study Start (ANTICIPATED): September 30, 2021
• Primary Completion (ANTICIPATED): October 31, 2024
• Study Completion (ANTICIPATED): October 31, 2024

Study Registration Dates

• First Submitted: June 28, 2021
• First Submitted That Met QC Criteria: July 30, 2021
• First Posted (ACTUAL): August 4, 2021

Study Record Updates

• Last Update Posted (ACTUAL): July 29, 2022
• Last Update Submitted That Met QC Criteria: July 26, 2022
• Last Verified: July 1, 2022

More Information

Terms related to this study

• Keywords: Total Hip Arthroplasties (THA); HIP7
• Other Study ID Numbers: HIP7.2020.10

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: Yes